NCT06056401

Brief Summary

Carbon dioxide (CO2) pneumoperitoneum and clasp-knife positioning are commonly used to improve surgical access during robot-assisted laparoscopic urological surgery. However, these methods are sometimes associated with several unwanted cardiopulmonary effects such as increased mean arterial pressure, decreased pulmonary compliance and functional residual capacity, increased peak inspiratory pressure, and respiratory acidosis in association with hypercarbia. Volume-controlled ventilation (VCV) is the most commonly used method of ventilation during general anesthesia. It provides fixed minute ventilation and pulmonary resistance, which affect airway pressure. In pressure-controlled ventilation (PCV), constant inspiratory airway pressure can be achieved by decelerating the flow. However, minute ventilation is not fixed . CO2 pneumoperitoneum in the clasp-knife positioning can influence hemodynamic variables, including blood pressure, heart rate, and cardiac output. This is because changes in airway pressure affect intrathoracic pressure and the function of the heart itself. In this randomized study, we investigated the effects of VCV and PCV on peak inspiratory pressure during robot-assisted laparoscopic urological surgery involving CO2 pneumoperitoneum in the clasp-knife position.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 24, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 24, 2023

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

March 8, 2023

Completed
7 months until next milestone

First Posted

Study publicly available on registry

September 28, 2023

Completed
Last Updated

September 28, 2023

Status Verified

September 1, 2023

Enrollment Period

4 months

First QC Date

March 8, 2023

Last Update Submit

September 20, 2023

Conditions

Keywords

Mechanical ventilationrobot-assisted surgery

Outcome Measures

Primary Outcomes (5)

  • Check the patient's ventilation effect at a specific time

    we recorded the patients' peak inspiratory pressure

    T1(15 minutes after induction of anesthesia)

  • Check the patient's ventilation effect at a specific time

    we recorded the patients' peak inspiratory pressure

    T2(15 minutes after position was changed)

  • Check the patient's ventilation effect at a specific time

    we recorded the patients' peak inspiratory pressure

    T3(30 minutes after pneumoperitoneum was established)

  • Check the patient's ventilation effect at a specific time

    we recorded the patients' peak inspiratory pressure

    T4(60 minutes after pneumoperitoneum was established)

  • Check the patient's ventilation effect at a specific time

    we recorded the patients' peak inspiratory pressure

    T5(15 minutes after pneumoperitoneum was released)

Study Arms (2)

VCV group

EXPERIMENTAL

For patients assigned in this group, after standard anesthesia, in which the following drugs were used (midazolam 0.05 mg / kg;propofol 1.5-2.5 mg / kg; sufentanil 0.3-0.5 μg / kg; and cisatracurium0.2-0.3 mg / kg), their mechanical ventilation mode was adjusted to the VCV mode.

Behavioral: record Hemodynamic variables, respiratory variables and arterial blood gas at specific times

PCV group

EXPERIMENTAL

For patients assigned in this group, after standard anesthesia, in which the following drugs were used (midazolam 0.05 mg / kg;propofol 1.5-2.5 mg / kg; sufentanil 0.3-0.5 μg / kg; and cisatracurium0.2-0.3 mg / kg), their mechanical ventilation mode was adjusted to the PCV mode.

Behavioral: record Hemodynamic variables, respiratory variables and arterial blood gas at specific times

Interventions

Hemodynamic variables, respiratory variables and arterial blood gas were measured and recorded 15 minutes after induction of anesthesia (T1), 15 minutes after establishment of a folding knife position (T2), 30 and 60 minutes after CO2 pneumoconiosis (T3 and T4), and 15 minutes after pneumoconiosis (T5). Hemodynamic variables measured included mean arterial pressure , heart rate , cardiac output, cardiac index, stroke volume index and stroke volume variation. Breathing variables include tidal volume, minute ventilation , respiratory rate , airway frontal pressure , mean airway pressure , plateaus airway pressure , peripheral oxygen saturation , oxygen saturation , and oxygen response . Arterial blood gas variables include pH value, arterial carbon dioxide, arterial oxygen pressure , alkali surplus , alveolar oxygen pressure , and bicarbonate of soda ion concentration .

PCV groupVCV group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing urological surgery in clasp-knife position
  • between the age of 18 and 65
  • America Society of Anesthesiologist Grades I-II.

You may not qualify if:

  • Morbid obesity
  • systolic blood pressure \< 90 mmHg)
  • heart rate \< 60 beats per minute or \> 100 beats per minute
  • peripheral blood oxygen saturation \< 90%
  • Complicated with severe liver and kidney injury.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cai Xinyuan

Guangzhou, Guangdong, 510060, China

Location

Study Officials

  • Wenqian Lin

    anesthesiology department of Sun Yat-sen University Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

March 8, 2023

First Posted

September 28, 2023

Study Start

October 15, 2022

Primary Completion

February 24, 2023

Study Completion

February 24, 2023

Last Updated

September 28, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

Locations